• Publications
  • Influence
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting. Expand
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
The association with longer overall survival suggests that FOLFIRI plus cetuximab could be the preferred first-line regimen for patients with KRAS exon 2 wild-type metastatic colorectal cancer. Expand
The Liver Tumor Segmentation Benchmark (LiTS)
In this work, we report the set-up and results of the Liver Tumor Segmentation Benchmark (LITS) organized in conjunction with the IEEE International Symposium on Biomedical Imaging (ISBI) 2016 andExpand
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or
In locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma, perioperative FLOT improved overall survival compared withperioperative ECF/ECX, and the number of toxic deaths was increased. Expand
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
It is demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer. Expand
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
The unique actions that gemcitabine metabolites exert on cellular regulatory processes serve to enhance the overall inhibitory activities on cell growth and is evidenced in very few other anticancer drugs. Expand
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Results support the efficacy and safety of an every-2-weeks treatment with gemcitabine plus cisplatin as first-line chemotherapy for locally advanced or metastatic pancreatic cancer. Expand
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Patients with left-sided tumors had a markedly better prognosis than those with right-sided tumor locations and a significant interaction was observed between primary tumor location and treatment for OS within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. Expand
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
In patients with resectable pancreatic cancer, presurgical and postresection CA 19-9 levels correlate with overall survival and thus may be combined with other factors for risk stratification, and most, but not all, reports indicate that serial levels of CA19-9 correlate with response to systemic therapy. Expand
Automatic Liver and Tumor Segmentation of CT and MRI Volumes using Cascaded Fully Convolutional Neural Networks
Validations on further datasets show that CFCN-based semantic liver and lesion segmentation achieves Dice scores over 94% for liver with computation times below 100s per volume. Expand